Om

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company that focuses on developing orally bioavailable small molecule drugs to address a range of diseases. The company's primary aim is to target diseases where significant unmet medical needs exist, particularly in areas such as inflammation, cancer, and liver disease. Can-Fite leverages its proprietary platform which targets A3 adenosine receptor (A3AR), a key therapeutic target implicated in these conditions. By developing drugs that modulate this receptor, the company seeks to provide innovative treatments for conditions like rheumatoid arthritis and psoriasis. With a strong foundation in clinical development, Can-Fite BioPharma operates at the intersection of pharmaceutical innovation and disease management, contributing to advancements within the biotechnology sector. Headquartered in Petach Tikva, Israel, the company plays a crucial role in expanding the therapeutic horizons for chronic and severe health conditions, thus holding significant potential impact within both domestic and global health markets.

Analytikerskøn

Baseret på 1 analytiker

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I CAN-FITE BIOPHARMA MED ENDAVU: Køb Can-Fite BioPharma ($CANF) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Can-Fite BioPharma, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.